CLINICAL TRIAL

Treatment for Glucose Metabolism Disorders

Recruiting · 18+ · All Sexes · San Antonio, TX

This study is evaluating whether a diet high in fat and low in carbohydrates may help treat type 2 diabetes.

See full description

About the trial for Glucose Metabolism Disorders

Eligible Conditions
Glucose Metabolism Disorders · Glucose Metabolism Disorders (Including Diabetes Mellitus) · Diabetes Mellitus, Type 2 · Energy Supply; Deficiency · Metabolic Diseases · Diabetes Mellitus · Type 2 Diabetes Mellitus

Treatment Groups

This trial involves 3 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Control Group 1
Standard weight maintaining diet
OTHER
Control Group 2
Weight maintaining isocaloric ketogenic diet
OTHER
Control Group 3
Weight maintaining isocaloric ketogenic diet
OTHER
+
Beta-hydroxy butyrate
DIETARYSUPPLEMENT

Eligibility

This trial is for patients born any sex aged 18 and older. There are 5 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Age from 18-70 years
BMI = 27.5-42 kg.m2
% The text states that HbA1c is between 7.0-10.5%. show original
My weight has been stable for the past three months. show original
Good general health
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Baseline to 10 days
Screening: ~3 weeks
Treatment: Varies
Reporting: Baseline to 10 days
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Baseline to 10 days.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Treatment will improve 5 primary outcomes and 10 secondary outcomes in patients with Glucose Metabolism Disorders. Measurement will happen over the course of Baseline to 10 days.

High density lipoproteins (HDL)
BASELINE TO 10 DAYS
Change in HDL
BASELINE TO 10 DAYS
Low density lipoproteins (LDL)
BASELINE TO 10 DAYS
Change in LDL
BASELINE TO 10 DAYS
Glycated hemoglobin test (HbA1c)
BASELINE TO 10 DAYS
Change in HbA1c
BASELINE TO 10 DAYS
Glycerol level
BASELINE TO 10 DAYS
Change in Glycerol level will be measured
BASELINE TO 10 DAYS
Urine Microalbumin excretion
BASELINE TO 10 DAYS
Change in urine microalbumin excretion
BASELINE TO 10 DAYS
Free Fatty Acid (FFA)
BASELINE TO 10 DAYS
Change in FFA will be measured
BASELINE TO 10 DAYS
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What causes glucose metabolism disorders?

In [type 1 diabetes](https://www.withpower.com/clinical-trials/type-1-diabetes), a significant decrease of insulin sensitivity may be caused by impaired beta-cell function. Diabetes-related factors affect beta-cell metabolism and impair beta-cell function. This impairment of insulin action and/or secretion is in turn associated with chronic hyperglycemia.

Anonymous Patient Answer

What are the signs of glucose metabolism disorders?

The high prevalence of glucose metabolism disorders was confirmed. A high prevalence of prediabetes was found, and the risk for developing diabetes was also high. Findings from a recent study of this study imply the need to intensify an earlier screening of glucose metabolism disorders by combining blood sugar levels and oral glucose tolerance test.

Anonymous Patient Answer

Can glucose metabolism disorders be cured?

It was not demonstrated whether the improved metabolic control will be maintained and the adverse events will be significantly reduced if the diabetes is cured. In a recent study, findings need to be further confirmed for the more common type of diabetes.

Anonymous Patient Answer

What is glucose metabolism disorders?

Diabetes mellitus (DM) is a metabolic disorder that arises from a body's inability to adequately utilize or store the glucose in the blood. DM affects about 7% of people in the USA.

Anonymous Patient Answer

How many people get glucose metabolism disorders a year in the United States?

About 11.5 million people have at least one type of glucose metabolism disorder and about 60% of these have two or more type. This prevalence may be rising as rates of obesity and diabetes continue. Patients with diabetes should be tested if they have any of the associated glucose metabolism disorders. These data provide a snapshot of this important disorder.

Anonymous Patient Answer

What are common treatments for glucose metabolism disorders?

It is important to use more effective medications when diabetic patients develop hypoglycaemic crises due to prolonged fasting. In some cases, treatment may be changed to avoid the potential complications (hypoglycaemia) of hypoglycemia.

Anonymous Patient Answer

Have there been other clinical trials involving treatment?

The majority of patients with T2DM had never participated in a treatment trial. Therefore they have not had the benefit of treatment. However, it is possible they are now benefiting from some other approach to medical care that has not yet been thoroughly explored in a rigorous clinical trial.

Anonymous Patient Answer

Does glucose metabolism disorders run in families?

We found a strong statistical (P = 0.02) association between the risk of T1DM and T2DM with FPG levels (P = 0.023). We also found a significant relationship to the age of diagnosis of T2DM (P = 0.015) as well as T2DM related to the FPG levels (P = 0.011). We found that the mean age of diagnosis of T1DM was earlier in the FPG range (FPG = 6.0-6.9 mmol/l) (P = 0.007). We also found a significant association between the FPG levels and the HbA1c levels (P = 0.012).

Anonymous Patient Answer

What are the latest developments in treatment for therapeutic use?

The recent advances in research show the potential of using a combination of drugs to treat and prevent diseases effectively. New therapies allow the treatments to be prescribed as necessary in order to treat or prevent many types of diseases. The recent innovations of nanomedicine allowed for much more drug to be introduced in a less aggressive manner. In the future, these developments in nanomedicine will help to help treat many types of diseases that have been around for decades. Some of the latest therapies are discussed in this article including new ways in prevention and treatments of cancer and HIV. All of these new ideas are being implemented to help improve human health in the future.

Anonymous Patient Answer

Have there been any new discoveries for treating glucose metabolism disorders?

There have been no new scientific discoveries for treating glucose metabolism disorders for the decade ending in 2008. There are still many unanswered questions about the mechanisms that underlie diabetes. If we are to understand the cause of the diseases, it is likely that we will have to find a way to prevent diabetes in the first place. Treating the disease has been disappointing so far.

Anonymous Patient Answer

Has treatment proven to be more effective than a placebo?

Given the high risk of bias (not all studies evaluated placebo comparability and many did not use all-comers/group comparison) these conclusions must await a thorough analysis of randomization procedures, quality of control and completeness of reporting in all studies. As a consequence, the present meta-analysis can be interpreted with great caution.

Anonymous Patient Answer

How serious can glucose metabolism disorders be?

GHDs are fairly common and serious, and the number of people with GHD's has continued to grow. Diabetes in GHDs occurs late in life, affecting nearly half of adults with the disease. In most cases, there is poor control of blood glucose and an increased risk of diabetes complications such as nephropathy, retinopathy, macrovascular and peripheral vascular disease and microvascular complications. In individuals with IGT, metabolic and CV disease is not common.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Glucose Metabolism Disorders by sharing your contact details with the study coordinator.